BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
A phase 2 trial of BCD-236 in triple-negative breast cancer, run by Biocad, now recruiting.
Overview
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer is a phase 2 interventional study registered as NCT07108309 by Biocad, with 124 participants planned, started 2024-07-15 and due to reach its primary completion in 2025-12. Interventions recorded: BCD-236 and Chemotherapy.
Similar pages
not linked directly; found by shared links- TrialAn Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Shares Biocad and the tag pipeline.
- TrialClinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Shares Biocad and the tag pipeline.
- TreatmentBCD-100
Shares Biocad and the tag pipeline.
- TrialProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialPersonalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialNuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Biocad and the tag pipeline.